Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea

다국어 초록 (Multilingual Abstract)

With increase of multi-drug resistant Escherichia coli in community-acquired urinary tractinfections (CA-UTI), other treatment option with a therapeutic efficacy and a low antibioticselective pressure is necessary. In this study, we evaluated in vitro susceptibility of E. coliisolates from CA-UTI to fosfomycin (FM), nitrofurantoin (NI), temocillin (TMO) as well astrimethoprim-sulfamethoxazole (SMX), ciprofloxacin (CIP) and cefepime (FEP). Theminimal inhibitory concentrations were determined by E-test or agar dilution methodaccording to the Clinical and Laboratory Standards Institute guidelines, using 346 E. colicollected in 12 Korean hospitals from March 2010 to February 2011. FM, NI and TMOshowed an excellent susceptibility profile; FM 100% (346/346), TMO 96.8% (335/346),and NI 99.4% (344/346). Conversely, resistance rates of CIP and SMX were 22% (76/346)and 29.2% (101/349), respectively. FEP still retained an activity of 98.5%. In Korea, NI andTMO in addition to FM are a good therapeutic option for uncomplicated CA-UTI, especiallyfor lower UTI.

참고문헌 (Reference)

1 김경영, "최근 2년간 전라남도 및 광주지역의 지역사회 획득성 요로감염에 이환된 여성 환자에서 동정된 Escherichia coli의 Ciprofloxacin 내성패턴" 대한비뇨기과학회 49 (49): 540-548, 2008

2 김봉영, "국내에서 지역사회 급성 신우신염 원인균의 항균제 감수성 결과에 근거하여 지역사회 급성 방광염 치료 항균제를 선택할 수 있는가?" 대한감염학회 44 (44): 269-274, 2012

3 Livermore DM, "What remains against carbapenem-resistant Enterobacteriaceae? evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline" 37 : 415-419, 2011

4 Balakrishnan I, "Temocillin use in England : clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae" 66 : 2628-2631, 2011

5 Lee SY, "Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3" 67 : 2843-2847, 2012

6 Clinical and Laboratory Standard Institute, "Performance standards for antimicrobial susceptibility testing: 15th informational supplement: CLSI document M100-S15" CLSI

7 Garau J, "Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline" 14 : 198-202, 2008

8 Ko KS, "In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood" 58 : 111-115, 2007

9 Hooton TM, "Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection" 22 : 65-72, 2003

10 Lee MY, "Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea" 60 : 146-153, 2010

11 Andrews JM, "BSAC standardized disc susceptibility testing method (version 10)" 66 : 2726-2757, 2011

12 Lee SJ, "Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System" 17 : 440-446, 2011